Sort   by:  
 Page size 
MetabolomicsMining for natural product antileishmanials in a fungal extract library
Leishmaniasis is a Neglected Tropical Disease caused by the insect-vector borne protozoan parasite, Leishmania species. Infection affects millions of the World’s poorest, however vaccines are absent and drug therapy limited. Recently, public-private partnerships have developed to identify new modes ...
2021-02-12 | MTBLS868 | MetaboLights
MetabolomicsMapping human microbiome drug metabolism by gut bacteria and their genes

Individuals vary widely in their drug responses, which can be dangerous and expensive due to treatment delays and adverse effects. Growing evidence implicates the gut microbiome in this variability, however the molecular mechanisms remain largely unknown. We measured the ability of 76 diverse hum...

2019-07-10 | MTBLS896 | MetaboLights
MetabolomicsCollected mass spectrometry data on monoterpene indole alkaloids from natural product chemistry research
MIADB: a cumulative collection of 172 tandem mass spectrometry (MS/MS) of a vast array of monoterpene indole alkaloids. Samples were analyzed using an Agilent LC-MS system composed of an Agilent 1260 Infinity HPLC coupled to an Agilent 6530 ESI-Q-TOF-MS operating in positive mode. A Sunfire analytic...
2018-12-03 | MTBLS142 | MetaboLights
MetabolomicsConsistency across multi-omics layers in a drug-perturbed gut microbial community
Multi-omics analyses are increasingly employed in microbiome studies to obtain a holistic view of molecular changes occurring within microbial communities exposed to different conditions. However, it is not always clear to what extent each omics data type contributes to our understanding of the comm...
2022-12-08 | MTBLS3129 | MetaboLights
MetabolomicsMolecular networking coupled to high-resolution mass spectrometry fragmentation reveals a multitude of urinary antihypertensive drug metabolites
Mass spectrometry is the current technique of choice in studying drug metabolism. High-resolution mass spectrometry (HR-MS) in combination with fragment analysis (MS/MS) has the potential to contribute to rapid advances in this field. However, the data emerging from such fragmentation spectra pose c...
2016-05-23 | MTBLS307 | MetaboLights
MetabolomicsAdjunctive ibuprofen in pre-extensively drug-resistant and extensively drug-resistant tuberculosis: a Phase IIA open-label pilot clinical trial

Drug-resistant tuberculosis (TB) remains a major global health challenge. Host-directed therapies (HDTs) aim to limit tissue damage, shorten treatment, and improve outcomes by modulating immune responses. We evaluated the safety and potential efficacy of adjunctive ibuprofen an inexpens...

2026-05-28 | MTBLS13376 | MetaboLights
MetabolomicsAn integrated drug repositioning analysis for sarcopenia

Global population aging with increased longevity has incurred a higher prevalence of sarcopenia. Sarcopenia is characterized by age-related muscle/strength loss and is becoming a highly important public health issue. The development of sarcopenia increases the risk of various adverse health outco...

2026-01-09 | MTBLS9582 | MetaboLights
MetabolomicsUntargeted metabolomics for triaging of cytochrome b inhibitors during Chagas’ disease drug discovery

Chagas’ disease, caused by infection with the protozoan parasite Trypanosoma cruzi, is a potentially fatal condition for which new treatments are urgently needed. Due to the lack of validated drug targets, phenotypic screening followed by target deconvolution is the dominant approach in Chagas’ d...

2026-01-12 | MTBLS13510 | MetaboLights
MetabolomicsMetabolomics guides rational development of a simplified cell culture medium for drug screening against Trypanosoma brucei
In vitro culture methods underpin many experimental approaches to biology and drug discovery. The modification of established cell culture methods to be more biologically relevant, or to optimise growth, is traditionally a laborious task. Emerging metabolomics technology enables rapid evaluation of ...
2015-05-14 | MTBLS49 | MetaboLights
MetabolomicsRabbit plasma metabolomic analysis of Nitroproston: a multi target natural prostaglandin based-drug (Untargeted study)
INTRODUCTION: Nitroproston® is a novel multi-target drug bearing natural prostaglandin E2 (PGE2) and nitric oxide (NO)-donating fragments for treatment of inflammatory and obstructive diseases (i.e. asthma and obstructive bronchitis). OBJECTIVES: To investigate the effects of Nitroproston® adm...
2019-08-27 | MTBLS727 | MetaboLights
Sort   by:  
 Page size